India, July 3 -- Biocon Biologics Ltd. (BBL), a global biosimilars company and subsidiary of Biocon Ltd., has received marketing authorisation from the European Commission (EC) for its Denosumab biosimilars—Vevzuo® and Evfraxy®—for use across the European Union.
Vevzuo® is approved for the prevention of bone complications in adults with advanced cancers that have spread to the bone, as well as for the treatment of adults and skeletally mature adolescents with giant cell tumour (GCT) of the bone. Evfraxy® has been authorised for the treatment of osteoporosis in men and postmenopausal women, as well as bone loss due to hormone ablation therapy in men with prostate cancer and long-term systemic glucocorticoid thera...